Annmarie is the lead for our Personalised Patient Experience research and jointly initiated and developed the Centre’s Patient and Public Involvement model.
She is Marie Curie Professor of Supportive and Palliative Care and Scientific Director of the Marie Curie Palliative Care Research Centre.
She is Chair of the NCRI Advanced Disease and End of Life work stream, and is joint lead for the Palliative and Supportive Care work package for the HCRW PRIME centre.
Annmarie is interested in complex interventions and the patient experience at all levels, including the real time assessment of the impact of trial processes and interventions for issues of equipoise and effectiveness. Her primary research area is difficult areas of treatment decision-making in advanced cancer where the decision to treat with chemotherapy or radiotherapy becomes uncertain due to side effects in advanced disease. In the Personalised Patient Experience workstream she is developing methods to integrate the patient's priorities and preferences in decisions about treatment so that treatment decisions are framed around subjective outcomes, to supplement objective clinical data.
She is also interested in the acute and late effects of cancer treatments, including past cure. She has developed a portfolio of qualitative studies embedded within oncology and supportive care clinical trials and national and international multicentre qualitative studies. She has a strong interest in PPI and is joint lead (with Pro Matthias Eberle) for Engagement and PPI for the School of Medicine at Cardiff University.
Alan is a Reader in Translational Virotherapies based within the Division of Cancer and Genetics at Cardiff University School of Medicine. Alan has long standing experience in developing targeted, advanced therapeutics, gained from previous positions at the University of Birmingham (1998 – 2003), King’s College London (2003 – 2005) and the University of Glasgow (2005 – 2013).
His team study the adenovirus, using detailed information about how viruses interact with cells to develop targeted, bespoke virotherapies for a diverse array of cancer types. His team are supported by programmatic funding from Cancer Research UK, as well as funding from Cancer Research Wales, Tenovus Cancer Care and Knowledge Economy Skills Scholarship (KESS 2).
Amongst his varied other roles, Alan is a long standing, founding member of the British Society for Gene and Cell Therapy (BSGCT). He has been an elected board member since 2014 – the first (and only) BSGCT board member based in Wales, and in 2020 became treasurer for the society. In 2017 Alan established an active BSGCT subcommittee committed to the development of Early Career Researchers within the Gene and Cell Therapy field, which now runs as an annual networking and careers focussed meeting.
Originally from the South Wales valleys, Lee’s undergraduate training was completed in Cardiff University, followed by a PhD at the Institute of Medical Genetics at (what was then) the University of Wales College of Medicine. His Cancer Research Wales funded PhD was completed in the laboratory of Professors Julian Sampson and Jeremy Cheadle on the "Molecular and Functional Analysis of the Human Tumour Suppressor Genes TSC1 and TSC2". Upon completing his PhD in 2002 he took up a Postdoctoral Fellow position at the Murdoch Children's Research Institute (MCRI) within the Royal Children's Hospital in Melbourne, Australia. His work there was a change of focus from the cancer genetics of my PhD as he worked in the research groups of Prof Henrik Dahl and David Thorburn on Complex I deficiency in mitochondria. Upon completing this post, he returned to Cardiff University and to cancer genetics, working on a Cancer Research UK funded project in the laboratory of Prof Alan Clarke. In July 2013 he took up a fellowship at the European Cancer Stem Cell Research Institute where his research group focuses on the prevention and early detection of colorectal cancer. Prevention research focusses on understanding how the interactions between an individual’s diet, microbiome, metabolome, epigenome and immune system impacts on the intestinal stem cell to create an anti- or pro-tumourigenic environment. Early detection work focusses on the use of oncotrophic bacteria as a theranostic to identify and potentially treat solid tumours.
Dr Kathy Seddon is an elearning specialist. A Churchill Fellowship allowed her to set up an online collaboration between European schools she researched the success of their online collaboration in her Exeter University Doctorate "Teacher Motivation, Learning and Practice in an International Online community" She is an honorary Fellow of Exeter University. Kathy has a number of publications arising from her thesis and from her work with the National College for School Leadership in their online communities.
After the death of her husband from a glioblastoma she wanted to put her research skills to use as a ‘Research Voice’ for Marie Curie working on ‘missing data’ and 'Impact of research'. Kathy is a Research partner at the WCRC and has helped (PPI) with a number of completed projects. She has been a co-applicant on key pieces of research such as Bereavement, RAMBO, and PETROS. She has an interest in ethical approval, brain tumour research and in MDRG groups
Dr Stephanie Smits is a behavioural scientist based in Cardiff University's Division of Population Medicine who works in the area of screening, prevention and early diagnosis of cancer. She is currently applying her behavioural science expertise to explore experience, completion and outcomes in bowel cancer screening for people with multi-morbidity in her Health and Care Research Wales fellowship. She has expertise in areas such as cancer awareness, screening, behaviour change, psychological theory and engaging hard to reach groups in research. She has an interest in bringing together data from different sources, including qualitative research, surveys and routinely held data, to reduce inequalities in cancer and improve outcomes at different stages of the patient pathway.
Eleanor joined the Wales Cancer Research Centre in 2018. Eleanor’s role involves undertaking responsibility for both our centre and the Cardiff Experimantal Cancer Medicine Centre (ECMC) in their reporting and finance requirements. Eleanor is involved in a variety of projects within our centre including supporting the development of early phase research activity, supporting the development of Cardiff's ECMC renewal bid, and the Cancer Research Strategy for Wales.
Eleanor has a background in research, the arts, and arts administration. She has worked with numerous arts organisations including Welsh National Opera, the Paul Hamlyn Foundation and Voluntary Arts Wales. Eleanor has experience supporting high level projects with complex stakeholder groups, and has both planned and conducted qualitative and quantitative research activities.